InSilico Medicine (03696.HK): Expects to Turn Profit in H1, Net Profit of US$33.5M to US$39.5M

InSilico Medicine Cayman TopCo (Stock Code: 3696) announced that based on a preliminary assessment of the group's unaudited consolidated management accounts for the six months ended 30 June 2026 and information currently available to the company, the group is expected to record: (i) revenue for the first half of 2026 of approximately US$102.5 million to US$106.5 million, representing an increase of approximately 272.7% to 287.3% compared to revenue of US$27.5 million for the six months ended 30 June 2025; (ii) net profit for the first half of 2026 of approximately US$33.5 million to US$39.5 million, compared to a net loss of US$19.2 million for the six months ended 30 June 2025; and (iii) adjusted non-IFRS net profit for the first half of 2026 of approximately US$35.5 million to US$41.5 million, compared to an adjusted non-IFRS net loss of approximately US$17.8 million for the six months ended 30 June 2025.

The board believes that the increase in revenue, net profit and adjusted non-IFRS net profit for the first half of 2026 is mainly due to the group's continued efforts to drive revenue growth, including a significant increase in revenue from out-licensing, co-development and research collaboration agreements in the first half of 2026 compared to the corresponding period in 2025, coupled with systematic improvements in operating efficiency. The company is still finalizing the group's interim results for the first half of 2026, and the information in this announcement is based solely on the board's preliminary assessment with reference to unaudited consolidated management accounts and currently available information, which has not been audited or reviewed by the company's auditors or audit committee and may be adjusted as necessary.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.